It is made available under a CC-BY-NC-ND 4.0 International license .

## Wastewater as a back door to serology?

Marie LittleFawn Agan, William R. Taylor, William A. Willis, Halee Lair, Anastasia Murphy, Anna Marinelli, Isaiah Young, Gari D. New, Md Ariful Islam Juel, Alex Dornburg, Mariya Munir, Jessica Schlueter, Cynthia Gibas

## Abstract

Wastewater surveillance is a powerful tool for monitoring the prevalence of infectious disease in urban populations, with predictive value for upcoming increases in cases and hospitalizations. The approach primarily used in disease surveillance has been to measure the number of viral copies detected in wastewater for a study area of known population, and systems for wastewater monitoring have been put in place worldwide during the SARS-CoV-2 pandemic. However, the potential to measure other biomarkers such as proteins and metabolites in wastewater has not been fully explored. Here we develop an approach to determine antibody optical density and titer measurements from wastewater. We measured abundance of anti-SARS-CoV-2 spike IgG and IgA from typical fresh samples of community wastewater, and from a collection of frozen samples dating from 2020-22. The assay described can be performed with readily available commercial reagents, at a moderate per-sample cost, facilitating non-invasive population level immune surveillance. Our findings demonstrate the feasibility of indirect serological surveillance through wastewater for population level monitoring, and the protocol described will enable the collection of larger data sets and development of models that can be leveraged to anticipate public health needs.

## Introduction

Wastewater surveillance has proven useful at both the regional scale for detection of SARS-CoV-2 infection trends<sup>1–3</sup>, and at the local scale for guiding rapid response to emerging outbreaks.<sup>4,5</sup> The main modes of wastewater surveillance during the COVID-19 pandemic have been quantitative detection and variant sequencing of viral RNA isolated from wastewater. However, the potential for monitoring other immunologically relevant molecules in wastewater has not been as extensively explored. Antibodies against SARS-CoV-2 offer a particularly promising target. Neutralization activity against SARS-CoV-2 is directly correlated with measurements of anti-SARS-CoV-2 IgG or IgA antibodies<sup>6</sup>. Decrease of community-wide antibody levels in a sewershed would reveal waning of a durable immune response in the population after episodes of widespread infection or after seasonal vaccination campaigns. Short-term longitudinal studies of SARS-CoV-2 neutralizing antibodies in naturally infected, vaccinated, or boosted individuals have made clear that antibody protection against future infection wanes within a period of months<sup>7,8</sup>. As governmental

It is made available under a CC-BY-NC-ND 4.0 International license .

interventions ebb globally and rates of booster vaccine uptake continue to decline, there is little doubt that COVID-19 will transition to an endemic disease<sup>9</sup>. Understanding the susceptibility of populations to future waves of infections is critical for mitigating an endemic state that results in unacceptable morbidity and mortality. Expanding the scope of surveillance to include detection of antibody levels therefore offers a proactive approach that can identify populations at risk of future infection.

Immunoassay systems have been widely used as a biotechnology tool for detection of SARS-CoV-2 RNA<sup>10,11</sup> and viral proteins.<sup>12</sup> However, human antibodies shed in urine and feces have not been targeted as a biomarker in wastewater. Fecal antibody levels are correlated with antibody levels in serum<sup>13</sup>, and antibodies have frequently been demonstrated as a potential biomarker for detection of viral<sup>14</sup> and parasitic infections<sup>15</sup> in human urine samples. Antibody measurements from fecal samples have been highlighted as a non-invasive means to rapidly monitor the immune status of wildlife<sup>16</sup>, and similar measurements are increasingly being used for studying various aspects of human health<sup>17,18</sup>. Infection by SARS-CoV-2 elicits the secretion of mucosal IgG and IgA antibodies<sup>19</sup>. The IgA response waxes and wanes rapidly, being detectable in serum within days of infection, before falling below the limit of detection within weeks. In contrast, the signal of the IgG response in serum rises more slowly and may persist for months<sup>20</sup>, potentially remaining above the limit of detection even longer (Figure 1). Coronavirus-specific antibodies are known to be recoverable from fecal samples in animal models<sup>21</sup>, which suggests human antibody recovery from wastewater is possible. To date, the focus of research in this area has been on detection of antibodies from individual clinical specimens. The feasibility of targeting antibodies in wastewater for surveillance of populations remains unknown.

Here we present a protocol for an enzyme-linked immunosorbent assay (ELISA) to detect anti-spike (S) IgG and IgA antibodies from wastewater. We assess how detection varies by dilution and demonstrate the functionality of our approach on both freshly collected and archived frozen samples. This offers a protocol that enables both new research directions in future monitoring, and retroactive studies of archived samples collected during the SARS-CoV-2 pandemic, thereby offering a novel niche for wastewater surveillance. Adding the ability to assay antibody levels in wastewater in tandem with viral detection and sequencing will increase the power of wastewater surveillance to provide data critical for public health policy and decision making.



Figure 1. Generalized timeline of antibody waxing and waning in the human immune response.

## **Materials and Methods**

Prototype antibody assays first suggested the possibility of antibody detection from wastewater. 24 hour influent samples were collected from a South Burlington, Vermont wastewater treatment plant. 1L wastewater samples were homogenized and incubated with shaking at 4°C for one hour. The homogenate was clarified via centrifugation, 3500rpm at 4°C for 15 minutes, followed by 13000 rpm at 4°C for an additional 15 minutes. The clarified sample was then filtered through a 0.2um filter and run on a protein-G agarose column. Fractions were collected and subsequently, spectrophotometry via Nanodrop produced a peak indicating the presence of immunoglobulins, specifically IgG. This assay was not suitable for use on a large scale due to the volume of input material required and the high cost and limited availability of protein-G agarose column material to process 1L volumes. Building upon this observation, we have developed a scalable protocol for quantification of IgG and IgA from wastewater using commercially available reagents.

Samples were collected from the study areas described in <sup>4</sup> and <sup>22</sup> following the study protocols described. Briefly, 24 hour composite samples were collected using ISCO portable autosamplers. For this study, three sites representative of typical wastewater surveillance sampling areas were selected. One of these is a high-traffic

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

single building, the UNC Charlotte Student Union. The second site (Greenway) is a trunkline manhole with a sub-sewershed collection area that encompasses the entire UNC Charlotte campus. The third site is the Mallard Creek wastewater treatment facility, which is the Charlotte Water treatment plant serving a larger area that includes the university. Samples were either processed fresh or archived following collection in 50mL conical tubes and stored at -80°C.

45mL of freshly collected wastewater sample was poured into 50mL conical tubes and centrifuged for 10 minutes at 10,000 x G at 20°C. Remaining supernatant liquid from centrifuged 50mL conicals was poured carefully into new 50mL conical tubes, making sure not to pour solid pellet/particles along with supernatant. Sample supernatants can be stored at -80° C until ready for filtration. 15mL of liquid sample supernatant was poured into each 30kD filtration tube (Millipore) and centrifuged for 60 minutes at 4000 x G at 20° C. Concentrated protein supernatant was removed from filtration tubes and stored at -80°C.

For ELISA detection of total human IgG and total human IgA, plates were pre-coated with specific antigen to human IgG by the manufacturer (Abcam), and the developer specifications were followed without modification. Briefly, a sandwich ELISA was performed using an antibody cocktail containing both capture and detector antibodies after addition of either neat or concentrated wastewater to the plate. The detector antibody is conjugated to horseradish peroxidase (HRP). After a 60 minute incubation with shaking at room temperature, the plates were washed thrice with proprietary wash buffer followed by the addition of the substrate tetramethylbenzidine (TMB) for 10 minutes. TMB detected HRP activity on bound antibodies. After 10 minutes, proprietary stop solution was added to stop the activity of TMB and change the pigment from blue (620 nm) to yellow (450 nm). After the addition of the stop solution, the plates were immediately read on a fluorescence plate reader (Biotek Synergy LX).

For ELISA detection of SARS-CoV-2 S protein-specific IgG, plates were pre-treated with SARS-CoV-2 S1 RBD protein by the manufacturer (Abcam), and the developer specifications were followed without modification. Briefly, concentrated wastewater was added to the pre-coated plates, and washed four times with proprietary wash buffer after 60 minutes of incubation with shaking. Biotinylated anti-human IgG was added post wash for 30 minutes with shaking and washed four times after incubation with wash buffer. HRP-conjugated streptavidin was added for 30 minutes and washed as above. Streptavidin has a high binding affinity to biotin, which was coupled to the anti-human IgG. After washing away excess HRP-streptavidin, TMB was added to the plate for 15 minutes to activate the HRP. After 15 minutes, proprietary stop solution was added to terminate the HRP/TMB reaction and the plate was read at 450 nm on a fluorescence plate reader (Biotek Synergy LX).

It is made available under a CC-BY-NC-ND 4.0 International license .

# Results

## Detection of bulk human IgG and IgA in fresh wastewater samples

We first assayed abundance of total human IgG and IgA in fresh wastewater samples dating from October 2022. After concentration, bulk human IgG and IgA were both detected at concentrations that exceeded the upper detection limit of the ELISA assay at all dilutions tested.





Figure 2a. Concentrated wastewater evaluated for total IgG by ELISA

Figure 2b. Concentrated wastewater evaluated for total IgA by ELISA

It is made available under a CC-BY-NC-ND 4.0 International license .

Standard Curve (OD450)	Negative Control (OD450)	Concentrated WW (dilution)	Average triplicate OD450 readings	
0.928	0.055	Neat	>4.000	
0.503	0.053	1:2	>4.000	
0.307	0.059	1:4	>4.000	
0.166	0.057	1:8	>4.000	
0.120	0.055	1:16	>4.000	

Table	1a	OD450	readings	of total	human	laG on	wastewater
IGDIC	10.	00100	rouunigo	or total	mannan	190 011	wallowator.

\*NB - per manufacturer's specifications, any reading greater than twice the negative control is deemed positive.

Table 1b. OD450 readings of total human IgA on wastewater.\*

Standard CurveNegative Contr(OD450)(OD450)		Concentrated WW (dilution)	Average triplicate OD450 readings
2.611	0.124	Neat	>4.000
1.577	0.227	1:2	>4.000
0.873	0.108	1:4	>4.000
0.485	0.099	1:8	>4.000
0.297	0.1	1:16	>4.000
0.197	0.103	1:32	>4.000

\*NB - per manufacturer's specifications, any reading greater than twice the negative control is deemed positive.

# Measurement of anti-SARS-CoV-2 spike protein antibodies

We next assayed specific human anti-SARS-CoV-2 spike protein IgG and IgA in concentrated samples. Both fresh and long term frozen samples were assayed. Both IgG and IgA anti-spike antibodies were detectable in quantities within or over the range of detection of the ELISA assay for fresh samples collected in October of 2022, and for frozen samples collected in February of 2022. However, samples collected in June of 2020, when Mecklenburg County NC had only experienced a cumulative 9294 known cases in a population of 1.12 million, do not show signal sufficiently above background to be classified as positive under the manufacturer's protocol. (Figures 3,4)

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 3 Concentrated wastewater evaluated for anti-SARS-Cov-2 S-Protein IgG by ELISA.

	Union Fresh 10/2022	Union Frozen 2/2022	Greenway Fresh 10/2022	Greenway Frozen 2/2022	MLC Fresh 10/2022	MLC Frozen 6/2020			
neat	2.58	2.36	0.971	0.519	0.599	0.088			
1:2	1.42	2.04	1.09	0.223	0.291	0.060			
1:4	0.705	1.21	0.972	0.135	0.189	0.061			
1:8	0.391	0.722	0.695	0.098	0.163	0.059			

Table 2. Average triplicate OD450 readings for COVID-19 S-Protein (S1RBD) Human IgG.\*

\*NB - per manufacturer's specifications, any value greater than twice the negative control is deemed positive. Average Negative Control OD450: 0.053

It is made available under a CC-BY-NC-ND 4.0 International license .

IgA was found to be present in higher abundance than IgG in recent fresh wastewater samples. This may reflect the impact of ongoing COVID-19 infections in the campus community during early fall semester 2022, which have also been visible as an ongoing SARS-CoV-2 viral load in on-campus wastewater in Fall of 2022. (Figure 4, Table 3)



Fig. 4 Concentrated wastewater evaluated for anti-SARS-Cov-2 S-Protein IgA by ELISA.

Table	3:	Average	triplicate	OD450	readings	for	COVID-19	S-Protein	(S1RBD)	Human
lgA.										

	Union Fresh 10/2022	Union Frozen 2/2022	Greenway Fresh 10/2022	Greenway Frozen 2/2022	MLC Fresh 10/2022	MLC Frozen 6/2020
neat	2.236	>4.000	0.952	0.865	0.475	0.107
1:2	1.632	3.772	0.751	0.704	0.401	0.103
1:4	0.973	2.889	0.601	0.516	0.268	0.1

\*NB - per manufacturer's specifications, any value greater than twice the negative control is deemed positive. Average Negative Control OD450: 0.091

# Discussion

Here we have developed a means to quantify anti-SARS-CoV-2 antibody measurements from wastewater. We demonstrate the ability of our approach to detect anti-S IgG and anti-S IgA. Using our approach we successfully quantify antibody levels from both fresh and archived frozen wastewater samples, facilitating active and retroactive studies of shed antibodies. Our approach enables the development of a suite of novel applications for wastewater surveillance that includes applications such as monitoring changes in the immune status of populations, and the creation of quantitative models linking wastewater antibody concentrations to probabilistic models of seroprevalence.

It may be expected that detection and measurement of antibody levels require concentration of very large volumes of wastewater, application of specialized processing methods, or that antibodies rapidly degrade in wastewater environments to undetectable undetectable levels. However, we have shown that such expectations are not the case. Human IgG and IgA are present in community wastewater in concentrations nearly the equivalent of those found in typical serum samples. We further show that specific SARS-CoV-2 antibodies can be detected with a readily available and relatively inexpensive protocol. The cost of the reagents used amounts to approximately \$42/sample. This is less than half of the cost of ddPCR tests for viruses in wastewater that cost approximately \$90/sample. The assays we used are validated to be resistant to detection of cross-reactive antibodies from other mammals, as well as to antibodies specific to other common human-infecting coronaviruses. Manufacturer-reported sensitivity of the assay is 94.7%, and specificity is 98.6%.<sup>23</sup> With such a cost-efficient and reliable assay, it now becomes feasible to perform the investigations needed to validate detected antibodies in wastewater as a public health indicator.

Current wastewater surveillance approaches for viruses such as SARS-CoV-2 on measurements of viral abundance that reflect viral shedding by focus already-infected individuals. Such data is invaluable for identifying infection outbreaks and informing the needs of immediate public health responses.<sup>24–26</sup> As antibody levels remain high weeks to months after infection <sup>27</sup>, the continual detection of antibodies alone may not have the power to reveal a local outbreak. However, antibody levels detected in wastewater could have substantial utility for proactive public health planning and actions. For example, antibody detection could enable agencies to address a community-wide waning of SARS-CoV-2 immunity with vaccination campaigns before infections become common. In such a case, expanding our assay to capture anti-nucleocapsid (N) and anti-S antibodies would empower differentiating recent circulating infection from waning of vaccine-mediated immunity. This is possible since commonly-used vaccines such as mRNA-1273 and BNT1262b currently elicit an immune response to the spike protein in isolation <sup>28</sup>. In contrast, natural infection with SARS-CoV-2 also elicits immune response to other components of the virus <sup>28</sup>.

Therefore, the absence of anti-N paired with high anti-S levels would reveal a signature of a durable vaccine response, while the absence of both would reveal a population that is potentially at risk for future infection.

Wastewater samples by nature aggregate antibodies from a few to hundreds or thousands of individuals, challenging a direct interpretation of antibody levels detected and immune status. However, approaches can be developed to generalize the immune status of a population. COVID-19 wastewater surveillance projects that submit to CDC's National Wastewater Surveillance System gather site metadata describing water flow rates and sewershed populations contributing to the collection point signal. Where that information is available, ELISA optical density or titer measurements may be extrapolated to a bulk copies per person measurement, in a way that is analogous to the handling of viral copy number data.<sup>29</sup> Because the protocol is able to detect antibodies in frozen archived wastewater samples, it becomes possible to analyze the SARS-CoV-2 pandemic retrospectively and to develop such models while simultaneously testing their predictive value against historic incidence levels. Leveraging existing samples collected throughout the COVID-19 pandemic to conduct historic longitudinal studies that simultaneously quantify concentrations of antibodies and integrate that information with viral load and case data for the corresponding sewershed population. Such an approach represents an exciting next step for determining the promise of antibody detection in wastewater.

A wastewater surveillance approach to antibody abundance would complement rather than replace traditional serology. Associating ELISA optical density or titer measurements to equivalent concentrations in serum is challenged by individual variation of the immune response<sup>30</sup> and heterogeneity in the rate of fecal shedding of detectable antibodies that is likely to be similar to heterogeneity in the rate at which viral particles are shed through feces.<sup>31,32</sup> Wastewater surveillance has the potential to fill gaps in geographic settings where population-wide serological studies are not feasible. and reveal vulnerable neighborhoods or populations with low or undetectable antibody levels. Such an approach may be particularly useful for identifying and mitigating geographic health disparities. In particular, vaccine-mediated immunity hinges on prompt boosting with updated vaccines that reflect circulating variants<sup>8</sup>. Currently rates of boosting in countries such as the United States are low and highly biased between populations<sup>33</sup>. As predicting the local impact of the next SARS-CoV-2 infection wave requires an estimate of the durability of the immune response from earlier vaccination or natural infection, wastewater-based assessments could allow such data to be rapidly collected and thereby identify populations at risk.

#### **References**

- 1. Peccia, J. *et al.* Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nat. Biotechnol.* **38**, 1164–1167 (2020).
- 2. Wu, F. *et al.* SARS-CoV-2 RNA concentrations in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases. *Sci. Total Environ.* **805**, 150121 (2022).
- 3. Weidhaas, J. *et al.* Correlation of SARS-CoV-2 RNA in wastewater with COVID-19 disease burden in sewersheds. *Sci. Total Environ.* **775**, 145790 (2021).
- 4. Gibas, C. *et al.* Implementing building-level SARS-CoV-2 wastewater surveillance on a university campus. *Sci. Total Environ.* 146749 (2021).
- 5. Johnson, W. *et al.* Effectiveness of building-level sewage surveillance during both community-spread and sporadic-infection phases of SARS-CoV-2 in a university campus population. *FEMS Microbes* (2022).
- Dolscheid-Pommerich, R. *et al.* Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. *J. Med. Virol.* 94, 388–392 (2022).
- Shrotri, M. *et al.* Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Healthy Longev* 3, e470–e480 (2022).
- 8. Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P. & Dornburg, A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2204336119 (2022).
- 9. Phillips, N. The coronavirus is here to stay here's what that means. *Nature* **590**, 382–384 (2021).
- 10. Lu, D. *et al.* Prospects and challenges of using electrochemical immunosensors as an alternative detection method for SARS-CoV-2 wastewater-based epidemiology. *Sci. Total Environ.* **777**, 146239 (2021).
- 11. Thongpradit, S. *et al.* The Detection of SARS-CoV2 Antigen in Wastewater Using an Automated Chemiluminescence Enzyme Immunoassay. *Int. J. Environ. Res. Public Health* **19**, (2022).
- 12. Guerrero-Esteban, T. *et al.* Sensitive SARS-CoV-2 detection in wastewaters using a carbon nanodot-amplified electrochemiluminescence immunosensor. *Talanta* **247**, 123543 (2022).
- 13. Kolmannskog, S. & Haneberg, B. Immunoglobulin E in feces from children with allergy. Evidence of local production of IgE in the gut. *Int. Arch. Allergy Appl. Immunol.* **76**, 133–137 (1985).
- 14. Niedrig, M., Patel, P., El Wahed, A. A., Schädler, R. & Yactayo, S. Find the right sample: A study on the versatility of saliva and urine samples for the diagnosis of emerging viruses. *BMC Infect. Dis.* **18**, 707 (2018).
- 15. Nagaoka, F., Yamazaki, T., Akashi-Takamura, S. & Itoh, M. Detection of Urinary Antibodies and Its Application in Epidemiological Studies for Parasitic Diseases. *Vaccines (Basel)* **9**, (2021).
- Watt, K. A., Nussey, D. H., Maclellan, R., Pilkington, J. G. & McNeilly, T. N. Fecal antibody levels as a noninvasive method for measuring immunity to gastrointestinal nematodes in ecological studies. *Ecol. Evol.* 6, 56–67 (2016).
- 17. Frehn, L. et al. Distinct patterns of IgG and IgA against food and microbial antigens

in serum and feces of patients with inflammatory bowel diseases. *PLoS One* **9**, e106750 (2014).

- 18. Lin, R. *et al.* Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. *J. Transl. Med.* **16**, 359 (2018).
- 19. Lehmann, M. *et al.* Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8 T cells. *Mucosal Immunol.* **14**, 1381–1392 (2021).
- 20. Townsend, J. P. *et al.* The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. *Lancet Microbe* **2**, e666–e675 (2021).
- 21. Decaro, N. *et al.* Fecal immunoglobulin A antibodies in dogs infected or vaccinated with canine coronavirus. *Clin. Diagn. Lab. Immunol.* **11**, 102–105 (2004).
- 22. Barua, V. B. *et al.* Tracking the temporal variation of COVID-19 surges through wastewater-based epidemiology during the peak of the pandemic: A six-month long study in Charlotte, North Carolina. *Sci. Total Environ.* 152503 (2021).
- COVID-19 S-Protein (S1RBD) Human IgG ELISA Kit (ab274340). https://www.abcam.com/covid-19-s-protein-s1rbd-human-igg-elisa-kit-ab274340.ht ml (2022).
- 24. Kirby, A. E. *et al.* Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 1242–1244 (2021).
- 25. McClary-Gutierrez, J. S. *et al.* Standardizing data reporting in the research community to enhance the utility of open data for SARS-CoV-2 wastewater surveillance. *Environ. Sci.* **9**, (2021).
- 26. Kantor, R. S. *et al.* Operationalizing a routine wastewater monitoring laboratory for SARS-CoV-2. *PLOS Water* **1**, e0000007 (2022).
- 27. Chen, Y. *et al.* Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. *Sci Immunol* eabp8328 (2022).
- Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA 326, 1533–1535 (2021).
- 29. Soller, J. *et al.* Modeling infection from SARS-CoV-2 wastewater concentrations: promise, limitations, and future directions. *J. Water Health* **20**, 1197–1211 (2022).
- 30. Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl. J. Med.* **382**, 2302–2315 (2020).
- Crank, K., Chen, W., Bivins, A., Lowry, S. & Bibby, K. Contribution of SARS-CoV-2 RNA shedding routes to RNA loads in wastewater. *Sci. Total Environ.* 806, 150376 (2022).
- 32. Miura, F., Kitajima, M. & Omori, R. Duration of SARS-CoV-2 viral shedding in faeces as a parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding dynamics model. *Sci. Total Environ.* **769**, 144549 (2021).
- 33. Routledge, I. *et al.* Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. *Nat. Commun.* **13**, 2451 (2022).